Recap: Pieris Pharmaceuticals Q2 Earnings

Shares of Pieris Pharmaceuticals PIRS rose 8% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 62.50% year over year to ($0.09), which beat the estimate of ($0.17).

Revenue of $11,246,000 higher by 110.92% year over year, which beat the estimate of $7,760,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Pieris Pharmaceuticals hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 10, 2020

Time: 08:00 AM

ET Webcast URL: https://www.pieris.com/news-and-events/upcoming-events

Price Action

Company's 52-week high was at $5.97

52-week low: $1.60

Price action over last quarter: Up 7.05%

Company Overview

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.